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A B S T R A C T
Multifunctional-therapeutic three-dimensional (3D) scaffolds have been prepared. These biomaterials are able
to destroy the S. aureus bacterial biofilm and to allow bone regeneration at the same time. The present study
is focused on the design of pH sensitive 3D hierarchical meso-macroporous 3D scaffolds based on MGHA
nanocomposite formed by a mesostructured glassy network with embedded hydroxyapatite nanoparticles,
whose mesopores have been loaded with levofloxacin (Levo) as antibacterial agent. These 3D platforms ex-
hibit controlled and pH-dependent Levo release, sustained over time at physiological pH (7.4) and notably
increased at infection pH (6.7 and 5.5), which is due to the different interaction rate between diverse Levo
species and the silica matrix. These 3D systems are able to inhibit the S. aureus growth and to destroy the
bacterial biofilm without cytotoxic effects on human osteoblasts and allowing an adequate colonization and
differentiation of preosteoblastic cells on their surface. These findings suggest promising applications of these
hierarchical MGHA nanocomposite 3D scaffolds for the treatment and prevention of bone infection.
Statement of Significance
Multifunctional 3D nanocomposite scaffolds with the ability for loading and sustained delivery of an an-
timicrobial agent, to eliminate and prevent bone infection and at the same time to contribute to bone regenera-
tion process without cytotoxic effects on the surrounding tissue has been proposed. These 3D scaffolds exhibit
a sustained levofloxacin delivery at physiological pH (pH 7.4), which increasing notably when pH decreases
to characteristic values of bone infection process (pH 6.7 and pH 5.5). In vitro competitive assays between
preosteoblastic and bacteria onto the 3D scaffold surface demonstrated an adequate osteoblast colonization in
entire scaffold surface together with the ability to eliminate bacteria contamination.
© 2017.
1. Introduction
Osteomyelitis (OM) is a bone infection with very important clin-
ical and socio-economic implications, which is mainly caused by the
pathogen Staphylococcus aureus (S. aureus). OM results in inflam-
matory reaction that leads to bone destruction (osteolysis), being ex-
tremely difficult to treat and may lead to patient death [1–4]. Bac-
teria reach the bone (usually medullar one) through hematogenous
route or by direct inoculation (trauma) developing an acute infection
with polymorphonuclear infiltrates, cytokines and an inflammatory re-
action. Then, a cavity (sequestrum) is provoked, where the bacteria
form a biofilm inside the bone. This biofilm involves a bacterial com-
munity embedded within a dense and protective extracellular matrix,
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which constitutes a primary barrier in its treating. Thus, bacteria
within the biofilm can evade both the host immunological response
and the action of antimicrobial agents [5–7]. OM treatment remains
a significant clinical challenge due to the disadvantages presented by
current therapies. Such therapies involve systemic antibiotics admin-
istration and surgery, with serious repercussions for the patients as
high incidence of side effects, prolonged hospital stays, and even, high
morbidity rate [8–11].
Recently, the scientific efforts are directed to the design of 3D
scaffolding that dynamically contribute to the regeneration process,
promoting integration, osteoconduction and angiogenesis, avoiding
bacterial infection and/or offering many other desired functions to
promote faster and secure healing [12–17]. Despite all the advance-
ments, there are still challenges to be addressed in the field of lo-
cal bone drug delivery including effective and sustained release con-
trol, prolonged drug stability and activity as well as the cell toxicity
[18,19]. Idealistically, the local release from 3D scaffolds should pre-
serve the stability of the loaded active molecules over time and en-
sure a precise control over the drug release rate [20]. This fact can be
https://doi.org/10.1016/j.actbio.2017.11.009
1742-7061/© 2017.
UN
CO
RR
EC
TE
D
PR
OO
F
2 Acta Biomaterialia xxx (2017) xxx-xxx
understood as a way of smart drug delivery. In this sense, pH respon-
sive approaches can allow a selective release approach either through
changing the solubility of the drug carrier or through cleaving of pH
responsive bonds upon variation of microenvironment pH [21,22].
Such pH variations, from physiological pH (7.4) to pH values between
6.7 and 5.5, are due to the production of metabolites as lactic acid by
the microorganism proliferation [23,24]. However, these pH respon-
sive devices, in the most of the cases do not response to these varia-
tions, detecting more abrupt pH changes [25].
Recently, hierarchical meso-macroporous 3D scaffolds based on
nanocomposite formed by nanocrystalline apatite uniformly embed-
ded into a mesostructured SiO2–CaO–P2O5 glass wall (MGHA) have
been fabricated by rapid prototyping technique [26–28]. These
MGHA 3D scaffolds have shown excellent properties as highly bioac-
tive behavior, enhanced biocompatibility, no induction of inflamma-
tory response, as well as good preosteoblast adhesion, colonization,
proliferation and differentiation (see supporting information Fig. S1).
Unlike other reported 3D systems [12–17,29,30], these MGHA 3D
scaffolds are made up exclusively of pure ceramic nanostructured ma-
terial and not ceramic-polymer combinations, which exhibit excellent
bioactivity together with greater homogeneity of these platforms. All
these characteristics suggest their great potential application as multi-
functional 3D biomaterials for both bone tissue engineering and local
drug delivery systems.
Herein, with the aim of using these MGHA 3D scaffolds for treat-
ment and prevention of OM, they have been loaded with levofloxacin
(Levo). This quinolone antibiotic has been chosen because: (i) it is a
broad spectrum antibiotic used in bone infection therapy, which pene-
trates into both trabecular and cortical bone, (ii) it minimizes the risk
of bacteria resistance and (iii) it exhibits different protonation states
(cationic, zwitterionic, and anionic states) as a function of pH, which
could lead to different interactions between Levo and silanol groups of
the mesoporous matrix [31–33]. Thus, this work is focused on the de-
sign of multifunctional MGHA 3D scaffolds with the ability of pH-re-
leasing Levo to inhibit the S. aureus growth and to destroy the biofilm,
and at the same time allowing an adequate osteoblast colonization.
For these purposes, in vitro Levo release has been performed at dif-
ferent pHs to confirm the pH-dependent release. The effectiveness of
these 3D hierarchical systems has been evaluated by both in vitro bac-
terium/bone cell co-culture model and on preformed Gram-positive
bacterial biofilms. Finally, the possible cytotoxic effects induced by
the highest Levo dose released from MGHA 3D scaffolds were eval-
uated with cultured human Saos-2 osteoblasts. In the present study,
MGHA 3D-Levo scaffolds have been designed with two objectives: i)
to prevent bacterial contamination after placing the scaffold in a bone
defect to act as a template for tissue formation and ii) to treat bone de-
fects caused by infection (osteomyelitis).
2. Materials and methods
2.1. Preparation and characterization of MGHA scaffolds
MGHA 3D scaffolds based on nanocomposite material were pre-
pared by rapid prototyping (RP) using methylcellulose (MC), as pre-
viously reported [27,28]. These 3D scaffolds have been characterized
by X-ray diffraction (XRD) in a Philips X’Pert diffractometer (Eind-
hoven, The Netherlands), equipped with Cu Kα (40 kV, 20mA). The
textural properties were determined by N2 adsorption porosimetry us-
ing a Micromeritics ASAP2020 analyzer (Norcross, USA). The sur-
face area (SBET) was determined using the multipoint Brunauer-Em-
mett-Teller method included in the software. The total pore volume
(Vp) was calculated from the amount of N2 adsorbed at a relative
pressure of 0.97. The average mesopore diameter (Dp) was obtained
from the adsorption branch of the isotherm by means of the Bar-
rett–Joyner–Halenda (BJH) method [34] Morphological structure
analysis was performed by scanning electron microscopy (SEM) using
a field emission JEOL JSM 6335F microscope (Tokyo, Japan) at an
acceleration voltage of 10kV. The nanostructure was characterized by
Transmission electron microscopy (TEM) was performed on a JEOL
3010 electron microscope (Jeol Ltd., Japan) operating at 300kV (Cs;
0.6mm, resolution 1.7 °A). The porosity was measured by Hg intru-
sion porosimetry in a Micromeritics Autopore IV 9500 device (Mi-
cromeritics Instrument Corporation, Norcross, GA, USA). Elemental
analyses (C, H, N) were carried out on a LECO CHNS-932 micro-
analyzer (Saint Joseph, Michigan, USA). Fourier Transform Infrared
(FTIR) spectroscopy was performed in a Thermo Nicolet Nexus spec-
trometer (Thermo Scientific, USA) from 4000 to 400cm−1, using the
KBr pellet method and operating in transmittance mode.
2.2. Levofloxacin loading into MGHA scaffolds
Levo incorporation into the MGHA 3D scaffolds was carried out
by the impregnation method [35]. For this propose, the 3D scaf-
folds were soaking individually (with a mass of 23± 2mg) in 3mL of
an Levo ethanolic solution [3.7mg/mL], at room temperature (RT),
as previous results in powder [35]. After 24h in orbital shaking at
200 rpm, they were removed, vigorous washed with pure ethanol and
dried at RT. The handling of these scaffolds was performed in the dark
conditions due to its sensitivity to light. The amount of drug incorpo-
rated was determined by elemental chemical analysis. Each load mea-
surement was performed in quadruplicate. The 3D scaffolds loaded
with Levo have been named as MGHA 3D-Levo scaffolds.
2.3. Levofloxacin release from MGHA 3D-Levo scaffolds
The release kinetic studies of Levo were carried out in phosphate
buffered saline (PBS) solution at different pHs: 5.5, 6.7 and 7.4, to
study the pH influence on the release kinetic. In these studies, each
MGHA 3D-Levo scaffolds (supported vertically with a Pt wire) has
been soaked in 15mL of PBS, with the pH adjusted previously, at
37°C and orbital shaking at 300 rpm. The media have been removed
daily. The Levo released has been quantified using a spectrofluorime-
ter Biotek Power wave XS, version 1.00.14 of the Gen5 program, with
a ƛexcitation = 292nm and ƛemmision = 494nm [33]. Different calibration
lines have been calculated at different pHs in a concentration range of
12–0.01μg/mL.
2.4. Antimicrobial activity of the MGHA-Levo scaffolds
Prior to the all in vitro tests, the samples were sterilized by UV
light radiation during 10min in both sides. Then the samples were im-
mersed in 6mL of PBS under a 5% CO2 atmosphere at 37°C for 1h
to become stabilized and eliminate some residual agents before the
in vitro culture. The efficacy against bacterial growth and biofilm has
been determined using the S. aureus 15981 laboratory strain, due to
the most of the bone infections are caused by this kind of bacteria
[16]. Briefly, bacteria were inoculated in tryptic soy broth (TSB; Bio-
Merieux, Marcy L’Etoile, France) and incubated overnight at 37°C
with orbital shaking at 200 rpm. After culture, bacteria were cen-
trifuged for 10min at 3500g at 22°C. The supernatant was then dis-
carded and the pellet was washed three times with sterile PBS. The
bacteria were then suspended and diluted in PBS to obtain a concen-
tration of 108 colony forming units (CFU) per mL; the bacterial con-
centration was determined by spectrophotometry using a visible spec-
trophotometer (Photoanalizer D-105, Dinko instruments). To deter
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mine their effectiveness over time against S. aureus growth, 3D scaf-
folds were soaked in 2mL of PBS containing bacteria at 108 CFU/mL
of concentration. This solution was removed daily during a period of
time of 1 to 15days. The presence or not of bacteria, as well as their
quantification, was determined on the PBS solution in contact with
the MGHA 3D-Levo scaffolds. The determination of bacteria amount
was performed by CFU in agar. In this sense, 10μL of this solution
was seeded onto TH agar and incubated at 37°C overnight and pos-
terior count. The minimum inhibitory concentration (MIC) of Levo
has been also calculated, obtaining a value of 0.06μg/mL for these ex-
periments. Moreover, a direct observation of MGHA 3D-Levo scaf-
fold surfaces was also performed by confocal microscope in a Biorad
MC1025 microscope. For these experiments, the samples were stained
for 15min with a Live/Dead® Bacterial Viability Kit (Backlight™).
Staining was performed with a mixture of dyes: SYTO 9 (live bacte-
ria/green) and propidium iodide (dead bacteria/red). SYTO 9 fluores-
cence was excited at 480/500nm, and the emitted fluorescence mea-
sured at 500nm, and propidium iodide fluorescence was excited at
490/635nm, with the emitted fluorescence measured at 618nm [36].
Controls with MGHA 3D scaffolds without Levo were always carried
out in all the experiments.
Moreover, the effectiveness of these MGHA 3D-Levo scaffolds
against biofilm, previously formed onto cover glass disks, was also de-
termined. For these purposes, S. aureus biofilms were previously de-
veloped by suspended cover glass disks in a bacteria solution of 108
bacteria per mL during 48h at 37°C and orbital stirring at 100 rpm.
In this case, the medium used was 66% TSB + 0.2% glucose to pro-
mote robust biofilm formation. After that, the cover glass disks con-
taining bacterial biofilm were localized onto six well culture plates
(CULTEK) in 6mL of new medium. Then, MGHA 3D-Levo scaffolds
were submerged avoiding the direct contact with biofilm coated glass
disk. After 24h of incubation, the glass-disk were washed three times
with sterile PBS, stained with a 3μL/mL of Live/Dead® Bacterial Vi-
ability Kit (Backlight™) and 5μL/mL of calcofluor solution to specif-
ically determine the biofilm formation, staining the mucopolysaccha-
rides layer (extracellular matrix in blue). Both reactants were incu-
bated for 15min at RT. Biofilm formation was examined in an Olym-
pus FV1200 confocal microscope [36].
2.5. In vitro co-culture studies. MC3T3-E1 preosteoblasts vs
Staphylococcus aureus
Since multifunctional 3D systems involve both antibiotic release
and bone regeneration processes, the need for a flexible in vitro test
system highly representative of in vivo conditions is of paramount im-
portance before carrying out any tests on animals. Such model sys-
tem allows more realistic assessment of different clinical treatment op-
tions in a rapid, cost-efficient, and safe manner, especially regarding
to test possibly host-toxic therapies [37,38]. Here, we have established
an in vitro bacterium/bone cell co-culture model system to evaluate
these 3D systems for the prevention and treatment of OM. A prelim-
inary, co-culture assays was carried out by seeding MC3T3-E1 cells
(a murine calvaria-derived pre-osteoblastic cell line used as an arche-
typal model of in vitro osteogenesis [39,40]) and S. aureus 15981 lab-
oratory strain on the 3D-scaffolds (MGHA and MGHA Levo scaf-
folds), concurrently performing the corresponding control studies of
osteoblasts and bacteria individually. First of all, the preosteoblastic
cells were grown in complete Dulbecco’s Modified Eagle’s Medium
(α-DMEM, Sigma Chemical Company, St. Louis, MO, USA) sup-
plemented with 2mM L-glutamine (BioWhittaker), 100μgml−1 peni-
cillin (BioWhittaker), 100gml−1 streptomycin (BioWhittaker) and fe-
tal bovine serum (FBS, Gibco) at 10% at 37°C
under atmosphere conditions of 95% humidity and 5% CO2. Medium
was changed every day until confluence reached ≈90%. Cells were
washed with PBS, harvested using 0.25% trypsin-EDTA solution
(Sigma Aldrich), counted with a Neubauer Hemocytometer and col-
lected. Cells were then centrifuged at 310g for 10min and suspended
in fresh medium without antibiotics at a density of 2·104 cells/mL.
Simultaneously, S. aureus bacteria were cultured in the same condi-
tions and taken at a density of 2× 108 cells/mL, mimicking an infec-
tious process. Then 500μL of both preosteoblast and bacteria suspen-
sions were seeded onto 3D scaffolds and incubated different times at
37°C under atmosphere conditions of 95% humidity and 5% CO2.
Then, the samples were washed twice with sterile PBS and fixed with
paraformaldehyde (Sigma Aldrich) 4% + 1% (w/v) sucrose (Sigma
Aldrich) in PBS for 40min. Afterwards, samples were again washed
with PBS and permeabilized with 0.5% Triton X-100 (Sigma Aldrich)
at 4 °C for 5min. Nonspecific union sites were blocked with 1% (w/
v) bovine serum albumin (BSA) (Sigma Aldrich) incubated at 37°C
for 20min. Finally, samples were stained with Atto 565 conjugated
with phalloidin (ratio 1:40, Sigma Aldrich) for cytoplasm α-F-actin
filaments dying and then stained 2min with 100μl of DAPI (Thermo
Fisher Scientific) for eukaryotic nuclei visualization and bacteria. Fi-
nally, the samples were washed with PBS and maintained in PBS for
confocal analysis. Moreover, lactate dehydrogenase activity (LDH)
was determined in the culture medium in contact with the 3D scaffolds
after 6, 24h and 3days of incubation to evaluate the plasma membrane
integrity. Activity of LDH released by the MC3T3-E1 cells is directly
related to the rupture of the plasma membrane that produces the re-
lease of enzymes present in the cytoplasm. Measurements were per-
formed by using a commercial kit (Spinreact) at 340nm with a Beck-
man DU 640 UV–Visible spectrophotometer Unicam UV-500 and cal-
culated in terms of absorbance variation by minute to obtain the units
per litre concentration (ΔA/min 4925= U/L LDH).
2.6. Culture cell for the in vitro biocompatibility studies
The in vitro biocompatibility assays were carried out on human
osteosarcoma Saos-2 cell line, which is usually used as experimental
model in this kind of in vitro studies due to its osteoblastic properties
as production of mineralized matrix, high alkaline phosphatase lev-
els, PTH receptors and osteonectin presence [41]. Human Saos-2 os-
teoblasts (purchased from American Type Culture Collection, ATCC)
were seeded on six well culture plates (CULTEK), at a density of
105 cell/mL in DMEM supplemented with 10% fetal bovine serum
(FBS, Gibco), 1mM L-glutamine (BioWhittaker), penicillin (200μg/
mL, BioWhittaker), and streptomycin (200 μg/mL, BioWhittaker), un-
der a CO2 (5%) atmosphere and at 37°C for 24h. MGHA and
MGHA-Levo scaffolds were soaked in 15mL of DMEM at 37°C and
orbital shaking at 200 rpm. obtaining the supernatants with the Levo
dose released after 3 and 24h. Controls of DMEM without scaffolds
were also prepared. All these media were added to cultured human
Saos-2 osteoblasts and cells were incubated for 24h. Then, cells were
washed with PBS, harvested using 0.25% trypsin-EDTA solution, and
counted with a Neubauer hemocytometer for the analysis of cell pro-
liferation. Cells were then centrifuged at 310g for 10min and resus-
pended in fresh medium for the analysis of viability, cell cycle, apop-
tosis, intracellular reactive oxygen species (ROS) content, cell size,
and complexity by flow cytometry as described below.
2.6.1 Flow cytometry studies
After incubation with the different probes, the conditions for the
data acquisition and analysis were established using negative and
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positive controls with the CellQuest Program of Becton Dickinson.
For statistical significance, at least 10,000 cells were analyzed in each
sample.
2.6.2 Cell viability and intracellular ROS content
After detachment of Saos-2 osteoblasts, cell suspensions were in-
cubated with 100μM 2’,7’-dichlorofluorescein diacetate (DCFH/DA)
at 37°C for 30min. DCF fluorescence was excited at 488nm and
measured with a 530/30nm band pass filter in a FACScalibur Becton
Dickinson flow cytometer. Cell viability was determined by addition
of propidium iodide (PI: 0.005% in PBS) to stain the DNA of dead
cells. The fluorescence of PI was excited at 488nm, and the emission
was measured with a 670nm LP in the cytometer described above.
2.6.3 Cell cycle analysis and apoptosis detection
Cell suspensions were incubated with Hoescht 33258 (Poly Sci-
ences, Hoechst 5μg/mL, ethanol 30%, and BSA 1% in PBS), used
as a nucleic acid stain, for 30min at RT in darkness. The Hoechst
fluorescence was excited at 350nm, and the emission was measured
at 450nm in a LSR Becton Dickinson flow cytometer. The cell per-
centage in each cycle phase: G0/G1, S, and G2/M was calculated with
the CellQuest Program of Becton Dickinson, and the SubG1 fraction
(cells with fragmented DNA) was used as indicative of apoptosis.
2.6.4 Cell size and complexity
After detachment of Saos-2 osteoblasts, forward angle (FSC) and
side angle (SSC) scatters were evaluated as indicative of cell size and
complexity respectively using a FACScalibur Becton Dickinson flow
cytometer.
2.7. Statistics
All data are expressed as means ± standard deviations of a represen-
tative of three experiments carried out in triplicate. Statistical analy-
sis was performed using the Statistical Package for the Social Sci-
ences (SPSS) version 19 software. Statistical comparisons were made
by analysis of variance (ANOVA). Scheffé test was used for post hoc
evaluations of differences among groups. In all of the statistical eval-
uations, p< .05 was considered as statistically significant.
3. Results and discussion
3.1. Characterization of the MGHA 3D-Levo scaffolds
A deep morphological and structural characterization of MGHA
3D-Levo scaffolds was carried out with different techniques and is
summarized in Fig. 1. By different SEM microscopies, a high and reg-
ular level of hierarchical porosity from macro to mesoporous ranges
are shown. In this sense, different scales of porosity can be observed:
(i) ultra-large macropores of ca. 450μm; (ii) macropores with di-
ameters of ca. 80μm interconnected and (iii) highly ordered meso-
pores in 2D hexagonal (p6mm, plain group) structure with diame-
ters of ca. 9nm. These results evidence the hierarchical structure of
MGHA 3D-Levo scaffolds. A study by mercury intrusion porosimetry
was carried out, confirming also that the Levo impregnation process
does not affected to the macroporous properties of these scaffolds
(data not shown). To confirm qualitatively the presence of Levo,
MGHA 3D-Levo scaffolds were characterized by FTIR (Fig. 1, bot-
tom). We can observe characteristic bands of Levo molecule (which
are indicated by arrows) to 3265cm−1 due to carboxylic
Fig. 1. Characterization of 3D MGHA scaffolds before and after Levo loading. (Top) Morphological and structural characterization by SEM and TEM showing a high a regular
level of hierarchical porosity from macro to mesoporous. (Bottom) FTIR spectra and N2 adsorption isotherms of 3D MGHA scaffolds before and after drug loading confirming the
presence of Levo and an decrease of textural properties in the mesoporous range.
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group, 2931cm−1 due to alkanes group stretching, 1724cm−1 due to
stretching of carbonyl group, 1294cm−1 due to stretching of amines,
between 1100 to and 1400cm−1 due to the presence of halogen group.
Once confirmed the presence of drug, a study by elemental chemical
analysis was carried out to calculate the amount of antibiotic loaded
by each scaffold. Moreover, the textural properties of these 3D scaf-
folds were analyzed by N2 adsorption porosimetry with the purpose to
determine the incorporation of Levo into their mesoporous structure.
Table 1 shows the percentage (%) of Levo in each MGHA 3D-Levo
scaffolds and the variation of their textural properties before and af-
ter impregnation process. Concerning to the yielding of the loading
process, MGHA 3D-Levo scaffolds loaded a 3% of Levo respect to
the total drug concentration used in the impregnation solution. Al-
though a priori, this percentage would seem low, it is within the nor-
mal range of loading of a drug by the impregnation method [42]. N2
adsorption studies (Fig. 1 and Table 1) show a significant decrease
in the textural properties, from values of 123m2/g and 0.2cm3/g for
specific surface area and total pore volume, respectively, to 40m2/g
and 0.1cm3/g before and after drug loading. Also, a slight varia-
tion in pore diameter was observed, exhibiting a value of
Table 1
Levo loaded (%) into the mesoporous structure of MGHA-Levo scaffolds. Textural
properties: BET surface area (SBET), pore volume (VP) and pore diameter (DP) before
and after the impregnation process.
Samples % Levo SBET (m
2/g) Vp (cm
3/g) Dp (nm)
MGHA – 123 0.2 10.0
MGHA-Levo 3 40 0.1 9.3
SBET is the specific surface area determined by the BET method. Vp is the total pore
volume calculated using the single point method at P/P0 = 0.99. Dp is the pore diameter
calculated from the analysis of the adsorption branch of the isotherm using the BJH
method.
9.3nm in the MGHA-Levo scaffolds versus 10nm in the MGHA scaf-
folds without Levo. It is known that the decrease in the values of spe-
cific surface area, total pore volume and pore diameter after drug load-
ing process is related to the confinement of the drug into the meso-
porous structure according with the literature [42].
Finally, to determine if the impregnation process affects to meso-
porous arrangement and crystallinity of both apatite phase of MGHA
scaffolds and the drug, XRD studies have been carried out. Fig. S2
shows XRD patterns at low and wide scattering angles correspond-
ing to a MGHA 3D-Levo scaffolds. Low angle XRD pattern (left)
shows a well-defined diffraction maximum at 2θ = 0.86 degree and
wide maxima around 2θ= 1.43 and 1.67 degree, which can be indexed
as 10, 11 and 20 reflections of a 2D-hexagonal structure with p6mm
plane group. Wide angle XRD pattern (right) reveals the presence
of nanocrystalline apatite phase exhibiting (002), (211) and (3 10)
reflections. These results highlight that Levo incorporation into the
mesoporous structure does not affect their mesostructural order, main-
taining the 2D-hexagonal structure and the crystallinity of the apatite
phase of the pore wall. Moreover, Levo is does not crystallize into
mesoporous network, as it has been also shown for other mesoporous
matrices and other drugs [43].
3.2. In vitro levofloxacin release kinetics
The in vitro drug release assays from MGHA 3D-Levo scaffolds
were carried out at different pH values in PBS to determine the pH-de-
pendent Levo release. Thus, pH 5.5 and pH 6.7 were used as repre-
sentative values of an infectious process, and pH 7.4 as value in phys-
iological conditions [23,25]. Fig. 2 displays in vitro release profiles,
which are expressed as accumulative drug release as function of the
time. The obtained results show significantly higher release at acid
pH values (pH 5.5 and 6.7) than that obtained at physiological con-
ditions (pH 7.4), which follows a slow and sustained drug release. In
Fig. 2. pH-dependentLevo release from MGHA-Levo scaffolds. (Left) In vitro release profiles to pH 5.5, pH 6.7 and pH 7.4. The curves represent the cumulative amount of Levo
released (Qt) with respect to the amount of Levo initially present in the scaffold (Q0) versus time. (Right) Levo acid-basic balance at different pHs. (Bottom) Scheme showing the
possible interactions between the silanol groups of the mesoporous matrix and the Levo ionizable groups to different pHs.
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general, the drug release kinetics from mesoporous matrices are gov-
erned, primarily by drug diffusion processes throughout the matrix.
Such drug diffusion processes are fitted, generally, to the Higuchi
model. However, our results suggest that in addition to the drug dif-
fusion process throughout the mesoporous matrix, a new component
is governing the drug release kinetics. Specifically, this new compo-
nent refers to the MGHA matrix-Levo interactions, as it has been pre-
viously reported for other silica matrix [44,45].
Fig. 2 shows a schematic representation of the different interac-
tions between silanol (Si-OH) groups of 3D scaffolds and Levo ioniz-
able groups. Levo molecule exhibit an isoelectric point of 7.1 with dif-
ferent pH-dependent protonation states i.e. cationic, zwitterionic, and
anionic forms. These different protonation states are due to the pres-
ence of 6-carboxylic acid and the N4 piperazinyl group in the Levo
molecule, with pKa values of 6.1 and 8.2, respectively. Concerning to
the MGHA matrix, SiOH groups have a pKa value of 4.5. Thus, at pH
5.5, the 3D scaffolds surface exhibits deprotonated (SiO−) negatively
charged and Levo molecule, is in cationic form, resulting fast release
as it is observed in the release kinetics. This situation changes slightly
at pH 6.7, where the most of the Si-OH groups are deprotonated and
Levo is in two different protonation states, i.e., in cationic form and as
zwitterion, coexisting both species. Zwitterionic species have the abil-
ity to form hydrogen bonds with silanol matrix, leading to a slower re-
lease at this pH as it has been reported elsewhere [33]. Finally, at pH
7.4, the most Levo molecules are in zwitterionic form, which favors
the formation of more hydrogen bonds, showing a slow and sustained
release, based on the high stability of the hydrogen bonds compared to
other electrostatic interactions [33].
These studies reveal that Levo release from MGHA 3D-Levo scaf-
folds is pH-dependent, since drug-carrier interaction and subsequent
release can be modulated by pH changes. Specifically, drug release
increases as decreasing pH. Also, the drug-carrier interaction is re-
versible, allowing Levo to be released in a sustained and/or con-
trolled manner. Thus, to confirm this hypotheses, the theoretical ki-
netic model adopted in this work considers first-order diffusion/con-
vection (kS) and drug association/dissociation (koff) following the Eq.
(1) [45]. This model leads to a decoupling of drug association/disso-
ciation with its diffusion/convection: fast release of initially free drug
molecules via diffusion/convection and slow release of bound drug
molecules, that is dictated by the dissociation process.
where Qt/Q0 correspond to accumulative amount of drug released with
respect to the amount of drug initially presents in the matrix, per unit
time. kS is the diffusion constant and, koff and kon correspond to dis-
sociation/association constants, respectively. The drug that does not
interact with the matrix is governed mainly by kS, whereas that the
drug-matrix interaction is governed by koff. In this model, the free en-
ergy difference (ΔG) between drug free and drug bound to the matrix
can also be calculated. This parameter determines the initial burst ef-
fect and, it is expressed in the Eq. (2).
where kB is the Boltzmann constant and, T is the system absolute
Temperature in Kelvin grades. Fitting experimental release patterns
to Eq. (1) allowed the determination of the experimental values for
ks, kon and koff. Then, ΔG was calculated from Eq. (2). The experimen-
tal results are summarized in Table 2. The obtained results show a no-
table increase in kS, koff and ΔG parameters, by decrease of pH.
At pH 7.4, the koff value is very low, which means that most of the
drug interacts with the matrix, having a small amount of drug disso-
ciated and therefore, low kS and ΔG. On the contrary, at pH 6.7, the
drug-matrix unions start to dissociate as consequence of changes in
the Levo protonation states. It results in an increase of the kS and koff
constants and of the ΔG parameter. Finally, the more significant in-
crease, is at pH 5.5. In this case, no Levo-matrix interactions are pos-
sible, obtaining the higher amount of Levo released. The obtained re-
sults confirm that the release profiles can be fitted to a kinetic model,
which combines two parameters, i.e. reversible interaction matrix drug
as function of pH and drug diffusion process throughout the matrix.
These pH dependent release are promising since nowadays, one of the
main risks of the drug sustained release over time is the appearance
of antibiotic-multiresistant strains [19,45,46]. Fortunately, the higher
amount of Levo released from MGHA scaffolds is produced as the
pH decreases, and it only occurs when there is a high bacterial prolif-
eration. Therefore, the pH-dependent Levo release from our systems
could minimize the risk of antibiotic resistant strains [46].
3.3. In vitro antimicrobial activity
The 3D MGHA-Levo scaffolds microbiological effectiveness was
determined studying the S. aureus growth inhibition. Fig. 3 displays
Levo dose daily released at pH 7.4 and pH 5.5 and its microbiological
activity against this strain after 7days of incubation. The MIC in these
conditions was of 0.06μg/mL, which is according to the MIC values
for S. aureus, obtaining by other authors [46]. The results evidence a
Levo daily dose higher than the MIC, during 7days of incubation. Af-
ter this time, colony forming unit (CFU) of this bacterial strain grew
in the agar plates, confirming loss of antimicrobial activity (data not
shown). A local antibiotic administration system provides therapeu-
tic benefits when it ensure a drug concentration adequate in the tis-
sue. This requires that the drug dose daily released is several times
higher than the MIC of the microorganism causing the infection [46].
Levo dose (μg/mL) daily released from MGHA-Levo scaffolds is, dur-
ing 7days, higher than the MIC for the bacterial strain studied, thus,
this system could be effective to prevent an implant-associated infec-
tion. A direct assay by confocal microscopy has been carried out for
demonstrating the microbiological effectiveness of the MGHA-Levo
scaffolds. Fig. 3 (bottom) details comparatively the MGHA scaffolds
surface without Levo (left) and MGHA-Levo scaffolds (right) after
7days of incubation with a S. aureus concentration [108 bacteria/mL]
daily renewed. Results show the MGHA scaffolds surface without
Levo completely covered of mantle of S. aureus. By the contract,
the MGHA-Levo scaffolds surface shows total absence of bacteria
demonstrating their effectiveness after 7days of incubation.
Fig. 4 summarizes the obtained results to determine the effec-
tiveness of Levo containing 3D MGHA scaffolds against S. aureus
Table 2
Kinetic parameters estimated in the Eq. (1). The parameters Koff(h
−1), Ks(h
−1),
ΔG(10−21J) and R2 correspond to drug-matrix dissociation/association constants, the
free energy difference and the correlation coefficient, respectively.
pH Koff (h
−1) Ks (h
−1) ΔG(10−21 J) R2
7.4 0.002 0.121 2.71 0.997
6.7 0.011 0.155 4.19 0.996
5.5 0.067 0.435 19.15 0.999
(1)
(2)
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Fig. 3. Levo dose profile daily released. (Top) Levo dose (μg/mL) released over time to pH 5.5 and pH 7.4. The antimicrobial activity against S. aureus has been evaluated in the
range of 30–0.02μg/mL, obtaining a value of MIC of 0.06μg/mL.* [108 bacteria/mL] daily renewed. (Bottom) A representative image of confocal microscopy.
Fig. 4. In vitro antimicrobial activity against S. aureus biofilm of MGHA-Levo scaffold by confocal microscopy. (Left) Preformed S. aureus biofilm stained by SYTO (Green, alive
bacteria) and Calcoflour (blue, mucopolysaccharide covered). (Right) scenario after 3days with 3D scaffolds treatment containing Levo showing almost the bacteria stained with IP
(read, dead bacteria).
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biofilm, showing almost the total biofilm destruction after 3days of
incubation. Before treatment (left image), the confocal image shows
the biofilm surface formed by lived bacteria (green) covered with mu-
copolysaccharide coating (blue). After 3days of treatment, the sce-
nario is significant different showing almost the total of bacteria dead
(red), demonstrating the effectiveness of these 3Dscaffolds against
gram–positive biofilm bacteria.
It has been demonstrated that most cases of osteomyelitis are
caused by S. aureus, however they can coexist with other bacteria
types with different etiology as S. epidermidis [5,19,24]. Moreover,
pathogenic characteristics of collection organisms are different to that
from clinical isolates (which can have up to 20% more genes [47]).
Therefore, although the results obtained in this study are promising, it
is important to remark that it is only a preliminary assay that need fur-
ther in vitro research (and obviously in vivo one) before considering
these results orientative for all important etiologies.
3.4. In vitro MC3T3-E1 preosteoblast and S. aureus co-culture
assays
To evaluate the multifunctional capability concerning to both an-
timicrobial activity and bone regeneration in an OM scenario, in vitro
MC3T3-E1/S. aureus co-culture assays were carried out. For this
purpose, MC3T3-E1 osteoblast-like cells and S. aureus were seeded
on both MGHA and MGHA-Levo 3D scaffold surfaces. The con-
centrations used were of 108 cfu/mL S. aureus (suspended in TSB)
and 104 MC3T3-E1 osteoblast-like cells/mL (suspended completed
medium DMEM). Fig. 5 provides two series of images (MGHA and
MGHA-Levo 3D scaffolds) of the time progress followed in co-cul-
ture assays highlighting the expected effects of the material in each
case. In the case of MGHA scaffolds without Levo, at longer times
(24 h), apoptotic cells appear as rounded red spots while the biofilm
maturation keeps in successful progress until a fully developed state
with osteoblast complete disruption and disappearance. In the case of
co-cultures on MGHA-Levo scaffold, the outcomes are much more in-
spiring than before. The confocal images after 6h show the absolute
absence of bacterial population adhered to the material surface and os-
teoblasts healthily attached and growing. Finally, posterior time im-
ages after 24h and 3days demonstrate the scaffold surface clean of
bacteria with an adequate cell colonization, evidencing again a great
biocompatibility, as it has also been demonstrated for others 3D sys-
tems with co-administration of vancomycin and BMP-2 on in vitro
co-culture [38].
On the other hand, lactate dehydrogenase (LDH) test was per-
formed to (i) assess the cytotoxicity caused by the biomaterial itself
(MGHA and MGHA-Levo 3D scaffolds) and (ii) evaluate the status of
preosteoblasts under the co-culture conditions. These results (data not
shown) show a significant increased LDH released in MGHA scaffold
co-culture conditions, which increases with time. This is due to the co-
existence of cells and bacteria, as the later ones have a cytotoxic ef-
fect on the osteoblasts. Moreover, negligible values of LDH released
both in osteoblasts monoculture on MGHA and on MGHA-Levo scaf-
folds are observed, proving no cytotoxic effect of both materials. Fi-
nally, results from MGHA-Levo scaffolds indicate a high efficiency of
the system for keeping preosteoblast viability in co-culture conditions
with bacteria.
3.5. In vitro biocompatibility studies of levofloxacin dosages
In an ideal delivery system, biocompatibility represents a basis
ground of requirements to be combined with the drug antimicrobial
effectiveness and adequate drug release kinetics, originating true mul-
tifunctional platforms for tissue regeneration. Biocompatibility stud-
ies should be carried out with the cell types with which the sys
Fig. 5. In vitro competitive co-culture MC3T3-E1/S. aureus after 6h, 24h and 3days of incubation onto MGHA and MGHA-Levo 3D scaffolds. Material refraction in green, preosto-
blastic nuclei and bacteria in blue (DAPI) and actin-fibrous of preosteoblast cytoplasm in red (phalloidin).
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tem comes into contact, analyzing the effects produced by the mate-
rial physicochemical characteristics and the concentration of antimi-
crobial agent released. Recently, MGHA scaffolds have demonstrated
excellent properties as highly bioactive behavior, enhanced biocom-
patibility, no induction of inflammatory response as well as good
preosteoblast adhesion, colonization, proliferation and differentiation
(supporting information, Fig. S1). These properties together with the
results of Levo release shown in this study, suggest their great po-
tential as multifunctional biomaterials for both bone tissue engineer-
ing and local drug delivery systems. Since Levo dose released from
MGHA-Levo scaffolds is always higher than MIC for S. aureus, is im-
portant to evaluate possible cytotoxic effects caused by it on human
Saos-2 osteoblasts. This cell type was cultured for 24h in the presence
of medium containing the Levo dose released at pH 7.4, after 3 and
24h. Specifically, studied doses were of 1.8μg/mL and 7.7μg/mL, re-
spectively, which corresponding to the maxim doses of Levo released.
Note that, the Levo dose released to the characteristic pH of infection
(pH 5.5) is 7.5μg/mL, similar to the maximum dose assayed in these
biocompatibility studies.
Fig. 6 shows the effects of Levo release on osteoblast cell cycle
analyzed flow cytometry. The cell cycle phases G0/G1, S and G2/
M correspond to repose/cytoplasm growth, DNA replication and mi-
tosis phase, respectively. SubG1, corresponding to DNA fragmenta-
tion, was used as indicative of apoptosis. As it can be observed, the
Levo doses released after 3 and 24h (1.8 μg/mL and 7.7μg/mL, re-
spectively) do not alter any phase of the cell cycle G0/G1, S and G2/M
of human Saos-2 osteoblasts. Moreover, SubG1 fraction indicates very
low levels of cell death by apoptosis in all the experimental conditions
assayed.
In order to know the possible cytotoxic effects on the cell size
and internal complexity of Saos-2 osteoblasts, these cell parameters
were evaluated by flow cytometry through FSC and 90° SSC light
scatters, respectively, and are represented in Fig. 7. These properties
are determined in part by plasma membrane, cytoplasm, mitochon-
dria, pinocytic vesicles and lysosomes. The results highlight that no
changes of these parameters were observed in Saos-2 osteoblasts cul-
tured with the Levo doses studied.
Fig. 8 represents cell viability and apoptosis percentages, intracel-
lular ROS content and cell proliferation values of Saos-2 osteoblasts
after culture with DMEM containing the Levo dose released after 24h,
i.e. 7.7μg/mL. No significant differences (p > .05) are observed in via-
bility and apoptosis of osteoblasts cultured with this dose, compared to
control samples and osteoblasts cultured without Levo (MGHA sam-
ple). Therefore, Levo dose released after 24h does not induce cellular
dead. Moreover, the effects of this dose (7.7 μg/mL) on osteoblast pro-
liferation and oxidative stress induced were also analyzed.
The results highlight that although the Levo dosage released after
the 24h is not cytotoxic, as it has been indicated above by the results
of cell viability (Fig. 8), cell cycle phases (Fig. 6), cell size and inter-
nal complexity (Fig. 7), there is a slight but significant delay (p < .05)
in the osteoblasts proliferation after being cultured with medium con-
taining the Levo dosage released after 24h (Fig. 8). However, no sig-
nificant differences (p> .05) were found when the ROS content of os-
teoblasts cultured with the medium containing Levo is compared with
Fig. 6. Effects of Levo dose released from MGHA-Levo scaffolds after 3 and 24h on the cell cycle of Saos-2 osteoblasts. Control: osteoblasts cultured in DMEM medium. MGHA
3h and MGHA 24h: osteoblasts cultured with medium which was in contact with MGHA scaffolds without Levo, after 3 and 24h, respectively. MGHA-Levo 3h and MGHA-Levo
24 h: osteoblasts cultured with.
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Fig. 7. Effects of Levo dose released from MGHA-Levo scaffolds after 3 and 24h on the light scattering properties of Saos-2 osteoblasts. Forward angle scatter (FCS, cell size)
versus 90° side angle scatter (SSC, cell internal complexity) after each treatment. Control: osteoblasts cultured in DMEM medium. MGHA 3h and MGHA 24h: osteoblasts cultured
with medium which was in contact with MGHA scaffolds without Levo after 3h and 24h, respectively. MGHA-Levo 3h and MGHA-Levo 24h: osteoblasts cultured with medium
containing the Levo dose released from MGHA-Levo scaffolds after 3h and 24h, respectively.
the ROS values of control samples and Saos-2 osteoblasts cultured
with supernatants of MGHA scaffolds without Levo (Fig. 8). Thus,
these results confirm that the Levo dosage released after 24 h from
MGHA scaffolds does not induce oxidative stress on Saos-2 os-
teoblasts.
4. Conclusions
Tridimensional nanocomposite scaffolds with a pH-dependent and
locally controlled Levo release have been designed. These 3D
nanocomposite scaffolds exhibit a sustained Levo delivery at physio
logical pH (pH 7.4), which increasing notably when pH decreases
to characteristic values of bone infection process (pH 6.7 and pH
5.5). This pH-dependent Levo release is able to inhibit the S. aureus
growth and to destroy a preformed biofilm, without cytotoxic effects
on human osteoblasts. Moreover, in vitro co-culture assays with pre-
osteoblasts and bacteria onto the 3D scaffold surface demonstrated an
adequate cell colonization of the entire MGHA-Levo scaffold and its
ability to eliminate bacterial contamination. Although further in vivo
research is necessary, these findings reveal the possible potential of
these 3D nanocomposite scaffolds to be used as therapeutic platforms
for treatment and prevention of bone infection.
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Fig. 8. Effects of Levo dose released from MGHA-Levo scaffolds after 24h on vi-
ability and apoptosis percentages, intracellular ROS content and proliferation values
of Saos-2 osteoblasts. Control: osteoblasts cultured in DMEM medium. MGHA: os-
teoblasts cultured with medium which was in contact with MGHA scaffolds without
Levo after 24h. MGHA-Levo: osteoblasts cultured with medium containing the Levo
dose released from MGHA-Levo scaffolds after 24h. Statistical significance: *p< .05.
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